Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Hold” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been assigned an average recommendation of “Hold” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.1250.

REPL has been the subject of a number of analyst reports. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Wedbush boosted their price objective on Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price objective on the stock in a research report on Friday, June 26th. Cantor Fitzgerald lowered Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC raised its position in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after purchasing an additional 33,574 shares during the period. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers lifted its stake in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after purchasing an additional 18,263 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

Shares of NASDAQ:REPL traded down $0.12 during mid-day trading on Friday, reaching $10.99. The stock had a trading volume of 2,304,258 shares, compared to its average volume of 2,858,889. The company has a market cap of $922.56 million, a P/E ratio of -3.25 and a beta of 0.86. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24. The business’s 50 day moving average price is $8.02 and its 200 day moving average price is $7.40. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Research analysts expect that Replimune Group will post -2.29 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.